The future of tumour-specific fluorescence-guided surgery for pancreatic cancer
Mené sur 11 patients atteints d'un adénocarcinome canalaire du pancréas (âge : au moins 19 ans), cet essai de phase I évalue la dose optimale et la toxicité du panitumumab-IRDye800CW, un anticorps couplé à un agent fluorescent destiné à améliorer la détection des tumeurs occultes durant l'intervention chirurgicale
A crucial issue in the surgical treatment of patients with pancreatic ductal adenocarcinoma is the absence of direct, real-time, intraoperative visualisation of the lesion and its metastases. An unacceptably high number of surgeries with curative intent for localised pancreatic ductal adenocarcinoma result in early locoregional recurrence, suggesting a weakness in our ability to completely remove the tumour at its resection bed and to recognise radiographically occult metastatic disease. There is a need for an agent to enhance the ability of surgeons to assess the tumour and metastases (if present), directly and in real-time. The ideal agent should be safe and cost-effective, with rapid pharmacokinetics and a high sensitivity and specificity to the tumour, lymph nodes, and metastases while sparing non-cancerous tissue.
The Lancet Gastroenterology & Hepatology , commentaire, 2019